| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1
* Department of Research and
University Medical Outpatient Department, University Hospital, CH-4031 Basel, Switzerland
1Correspondence: Department of Research and University Medical Outpatient Department, University Hospital, CH-4031 Basel, Switzerland. E-mail: ebattegay{at}uhbs.ch
Angiogenesis and vascular cell proliferation are pivotal in physiological and pathological processes including atherogenesis, restenosis, wound healing, and cancer development. Here we show that mammalian target of rapamycin (mTOR) signaling plays a key role in hypoxia-triggered smooth muscle and endothelial proliferation and angiogenesis in vitro. Hypoxia significantly increased DNA synthesis and proliferative responses to platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in rat and human smooth muscle and endothelial cells. In an in vitro 3-dimensional model of angiogenesis, hypoxia increased PDGF- and FGF-stimulated sprout formation from rat and mouse aortas. Hypoxia did not modulate PDGF receptor mRNA, protein, or phosphorylation. PI3K activity was essential for cell proliferation under normoxic and hypoxic conditions. Activities of PI3K-downstream target PKB under hypoxia and normoxia were comparable. However, mTOR inhibition by rapamycin specifically abrogated hypoxia-mediated amplification of proliferation and angiogenesis, but was without effect on proliferation under normoxia. Accordingly, hypoxia-mediated amplification of proliferation was further augmented in mTOR-overexpressing endothelial cells. Thus, signaling via mTOR may represent a novel mechanism whereby hypoxia augments mitogen-stimulated vascular cell proliferation and angiogenesis.—Humar, R., Kiefer, F. N., Berns, H., Resink, T. J., Battegay, E. J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling.
Key Words: microvessels • smooth muscle • endothelium • embryogenesis • neovascularization
This article has been cited by other articles:
|
|
 |
|
  C. Cutler, K. Stevenson, H. T. Kim, P. Richardson, V. T. Ho, E. Linden, C. Revta, R. Ebert, D. Warren, S. Choi, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation Blood, December 1, 2008; 112(12): 4425 - 4431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jimeno, M. A. Rudek, P. Kulesza, W. W. Ma, J. Wheelhouse, A. Howard, Y. Khan, M. Zhao, H. Jacene, W. A. Messersmith, et al. Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors J. Clin. Oncol., September 1, 2008; 26(25): 4172 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hochegger, G. L. Jansky, A. Soleiman, A. M. Wolf, A. Tagwerker, C. Seger, A. Griesmacher, G. Mayer, and A. R. Rosenkranz Differential Effects of Rapamycin in Anti-GBM Glomerulonephritis J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1520 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, K. Hazell, E. Martinelli, S. R. y Cajal, S. Jones, L. Vidal, et al. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors J. Clin. Oncol., April 1, 2008; 26(10): 1603 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, P. Maione, and A. Rossi The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer Oncologist, February 1, 2008; 13(2): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Pak, A. Aldashev, D. Welsh, and A. Peacock The effects of hypoxia on the cells of the pulmonary vasculature Eur. Respir. J., August 1, 2007; 30(2): 364 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Mosley, J. T. Poirier, D. D. Seachrist, M. D. Landis, and R. A. Keri Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer Mol. Cancer Ther., August 1, 2007; 6(8): 2188 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wan and L. J. Helman The Biology Behind mTOR Inhibition in Sarcoma Oncologist, August 1, 2007; 12(8): 1007 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Kurmasheva, F. C. Harwood, and P. J. Houghton Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors Mol. Cancer Ther., May 1, 2007; 6(5): 1620 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Li, M. Petrimpol, K. D. Molle, M. N. Hall, E. J. Battegay, and R. Humar Hypoxia-Induced Endothelial Proliferation Requires Both mTORC1 and mTORC2 Circ. Res., January 5, 2007; 100(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Birle and D. W. Hedley Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther., October 1, 2006; 5(10): 2494 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Del Bufalo, L. Ciuffreda, D. Trisciuoglio, M. Desideri, F. Cognetti, G. Zupi, and M. Milella Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus Cancer Res., June 1, 2006; 66(11): 5549 - 5554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schultz, B. L. Fanburg, and D. Beasley Hypoxia and hypoxia-inducible factor-1{alpha} promote growth factor-induced proliferation of human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2528 - H2534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A K Mitra and D K Agrawal In stent restenosis: bane of the stent era. J. Clin. Pathol., March 1, 2006; 59(3): 232 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. O'Reilly, M. O. Leonard, N. Kieran, K. M. Comerford, E. Cummins, M. Pouliot, S. B. Lee, and C. T. Taylor Hypoxia induces epithelial amphiregulin gene expression in a CREB-dependent manner Am J Physiol Cell Physiol, February 1, 2006; 290(2): C592 - C600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve Cancer Res., December 1, 2005; 65(23): 11044 - 11050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Lanner, M. Raper, W. M. Pratt, and R. A. Rhoades Heterotrimeric G Proteins and the Platelet-Derived Growth Factor Receptor-{beta} Contribute to Hypoxic Proliferation of Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., October 1, 2005; 33(4): 412 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Dames, J. M. Mulet, K. Rathgeb-Szabo, M. N. Hall, and S. Grzesiek The Solution Structure of the FATC Domain of the Protein Kinase Target of Rapamycin Suggests a Role for Redox-dependent Structural and Cellular Stability J. Biol. Chem., May 27, 2005; 280(21): 20558 - 20564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V. M.-D. Mas, D. Benzaquen, G. Laurent, F. Huguet, and B. Payrastre Antileukemic activity of rapamycin in acute myeloid leukemia Blood, March 15, 2005; 105(6): 2527 - 2534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Kwon, H. S. Hong, J. C. Kim, J. S. Shin, and Y. Son Inhibitory Effect of Rapamycin on Corneal Neovascularization In Vitro and In Vivo Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 454 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Gerasimovskaya, D. A. Tucker, and K. R. Stenmark Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation J Appl Physiol, February 1, 2005; 98(2): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Frost, F. Moatamed, B. Hoang, Y. Shi, J. Gera, H. Yan, P. Frost, J. Gibbons, and A. Lichtenstein In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model Blood, December 15, 2004; 104(13): 4181 - 4187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kokkonen, A. Rivinoja, A. Kauppila, M. Suokas, I. Kellokumpu, and S. Kellokumpu Defective Acidification of Intracellular Organelles Results in Aberrant Secretion of Cathepsin D in Cancer Cells J. Biol. Chem., September 17, 2004; 279(38): 39982 - 39988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Y. Cheng, L. G. D. Fryer, D. Carling, and P. R. Shepherd Thr2446 Is a Novel Mammalian Target of Rapamycin (mTOR) Phosphorylation Site Regulated by Nutrient Status J. Biol. Chem., April 16, 2004; 279(16): 15719 - 15722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Martin-Puig, E. Temes, G. Olmos, D. R. Jones, J. Aragones, and M. O. Landazuri Role of Iron (II)-2-Oxoglutarate-dependent Dioxygenases in the Generation of Hypoxia-induced Phosphatidic Acid through HIF-1/2 and von Hippel-Lindau-independent Mechanisms J. Biol. Chem., March 5, 2004; 279(10): 9504 - 9511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Crawford, S. Jovanovic, G. R. Budas, A. M. Davies, H. Lad, R. H. Wenger, K. A. Robertson, D. J. Roy, H. J. Ranki, and A. Jovanovic Chronic Mild Hypoxia Protects Heart-derived H9c2 Cells against Acute Hypoxia/Reoxygenation by Regulating Expression of the SUR2A Subunit of the ATP-sensitive K+ Channel J. Biol. Chem., August 15, 2003; 278(33): 31444 - 31455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Heidemann, H. Ogawa, M. B. Dwinell, P. Rafiee, C. Maaser, H. R. Gockel, M. F. Otterson, D. M. Ota, N. Lugering, W. Domschke, et al. Angiogenic Effects of Interleukin 8 (CXCL8) in Human Intestinal Microvascular Endothelial Cells Are Mediated by CXCR2 J. Biol. Chem., February 28, 2003; 278(10): 8508 - 8515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Stenmark and S. A. Gebb Lung Vascular Development: Breathing New Life Into An Old Problem Am. J. Respir. Cell Mol. Biol., February 1, 2003; 28(2): 133 - 137. [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. SOMLYO, C. PHELPS, C. DIPIERRO, M. ETO, P. READ, M. BARRETT, J. J. GIBSON, M. C. BURNITZ, C. MYERS, and A. P. SOMLYO Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants FASEB J, February 1, 2003; 17(2): 223 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Kenerson, L. D. Aicher, L. D. True, and R. S. Yeung Activated Mammalian Target of Rapamycin Pathway in the Pathogenesis of Tuberous Sclerosis Complex Renal Tumors Cancer Res., October 15, 2002; 62(20): 5645 - 5650. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
